Page 43 - Demo

ANALESRANFwww.analesranf.comwith Severe Hemophilia A. N Engl J Med2024; 391: 235-46.https://doi.org/10.1056/NEJMoa2312611.15. Callaghan MU, Negrier C, Paz-Priel I, et al.Long-term outcomes with emicizumabprophylaxis for hemophilia A with or withoutFVIII inhibitors from the HAVEN 1-4 studies.Blood 2021; 137: 2231-42.https://doi.org/10.1182/blood.2020009217.16. The Lancet Global Health. The landscape forrare diseases in 2024. Lancet Glob Health2024; 12: e341.https://doi.org/10.1016/S2214-109X(24)00056-1.17. Vink%u0161el M, Writzl K, Maver A, et al. Improvingdiagnostics of rare genetic diseases with NGSapproaches. J Community Genet 2021; 12:247-56. https://doi.org/10.1007/s12687-020-00500-5.18. Choon YW, Choon YF, Nasarudin NA, et al.Artificial intelligence and database for NGSbased diagnosis in rare disease. Front Genet2024; 14: 1258083.https://doi.org/10.3389/fgene.2023.1258083.19. Lopes-J%u00fanior LC, Ferraz VEF, Lima RAG, et al.Health Policies for Rare Disease Patients: AScoping Review. Int J Environ Res PublicHealth 2022; 19: 15174.https://doi.org/10.3390/ijerph192215174.20. Bannister JB. Regulating Rare Disease: SafelyFacilitating Access to Orphan Drugs. FordhamLaw Rev 2018; 86: 1889- 921. PMID:29993206.21. Buckle N, Doyle O, Kodate N, et al. Theeconomic impact of living with a rare diseasefor children and their families: a scopingreview protocol. HRB Open Res 2024; 6: 41.https://doi.org/10.12688/hrbopenres.13765.2.22. Yang TL, Cui J, Rehumtulla A, et al. TheStructure and Function of Murine Factor Vand Its Inactivation by Protein C. Blood 1998;91: 4593-9. PMID: 9616155.23. De Pablo-Moreno JA, Liras A, Revuelta L.Standardization of Coagulation Factor VReference Intervals, Prothrombin Time, andActivated Partial Thromboplastin Time in Micefor Use in Factor V Deficiency PathologicalModels. Front Vet Sci 2022; 9: 846216.https://doi.org/10.3389/fvets.2022.846216.Coagulation: Homeostasis, Disease, andTreatment, with a Focus on the VonWillebrand Factor and Factors VIII and V. IntJ Mol Sci 2022; 23: 8283.https://doi.org/10.3390/ijms23158283.5. Monagle P, Massicotte P. Developmentalhaemostasis: Secondary haemostasis. SeminFetal Neonatal Med 2011; 16: 294-300.https://doi.org/10.1016/j.siny.2011.07.007.6. Grover SP, Mackman N. Intrinsic Pathway ofCoagulation and Thrombosis: Insights FromAnimal Models. Arterioscler Thromb Vasc Biol2019; 39: 331-8.https://doi.org/10.1161/ATVBAHA.118.312130.7. Palta S, Saroa R, Palta A. Overview of thecoagulation system. Indian J Anaesth 2014;58: 515-23. https://doi.org/10.4103/0019-5049.144643.8. De Pablo-Moreno JA, Miguel-Batuecas A, DeSancha M, et al. The Magic of Proteases:From a Procoagulant and AnticoagulantFactor V to an Equitable Treatment of ItsInherited Deficiency. Int J Mol Sci 2023; 24:6243.https://doi.org/10.3390/ijms24076243.9. Mukhopadhyay S, Johnson TA, Duru N, et al.Fibrinolysis and Inflammation in VenousThrombus Resolution. Front Immunol 2019;10: 1348.https://doi.org/10.3389/fimmu.2019.01348.10. McMurry HS, Jou J, Shatzel J. The hemostaticand thrombotic complications of liverdisease. Eur J Haematol 2021; 107: 383-92.https://doi.org/10.1111/ejh.13688.11. Tabibian S, Shiravand Y, Shams M, et al. AComprehensive Overview of CoagulationFactor V and Congenital Factor V Deficiency.Semin Thromb Hemost 2019; 45: 523-43.https://doi.org/10.1055/s-0039-1687906.12. Weyand AC, Flood VH. Von Willebrand Disease:Current Status of Diagnosis and Management.Hematol Oncol Clin North Am 2021; 35: 1085-101.https://doi.org/10.1016/j.hoc.2021.07.004.13. Castaman G, Matino D. Hemophilia A and B:molecular and clinical similarities anddifferences. Haematologica 2019; 104: 1702-9. https://doi.org/10.3324/haematol.2019.221093.14. Malec L, Peyvandi F, Chan AKC, et al.Efanesoctocog Alfa Prophylaxis for ChildrenD%u00e9ficit de factor V y terapias avanzadasAntonio Liras et al. 41 An. R.Acad. Farm.Vol. 91. n%u00ba 1 (2025) %u00b7 pp. 17-44